ArticlePharmacoEconomics2026

Application of a Prevalence-Adjusted Cost-Effectiveness Threshold Framework for Pulmonary Arterial Hypertension.

Adnan Alsumali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.